Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure

Dopamine agonists have been studied in chronic heart failure, but earlier reports with non-selective compounds demonstrated unfavourable long-term effects. CHF 1035 is an orally active, new selective dopamine agonist, primarily activating DA2- and alpha2 receptors, thereby inhibiting norepinephrine...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 2001-03, Vol.15 (2), p.139-145
Main Authors: TJEERDSMA, Geert, VAN WIJK, Leen M, MOLHOEK, G. Peter, BOOMSMA, Frans, HAAKSMA, Jaap, VAN VELDHUISEN, Dirk J
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cardiac Output, Low - drug therapy
Cardiovascular system
Dopamine Agents - therapeutic use
Double-Blind Method
Electrocardiography
Electrocardiography, Ambulatory
Esters
Female
Hemodynamics - drug effects
Humans
Male
Medical sciences
Middle Aged
Miscellaneous
Naphthalenes - therapeutic use
Norepinephrine - blood
Pharmacology. Drug treatments
Tetrahydronaphthalenes
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dopamine agonists have been studied in chronic heart failure, but earlier reports with non-selective compounds demonstrated unfavourable long-term effects. CHF 1035 is an orally active, new selective dopamine agonist, primarily activating DA2- and alpha2 receptors, thereby inhibiting norepinephrine release, which may be beneficial in heart failure. We conducted a double-blind, placebo-controlled comparison of CHF 1035 (10 mg/day, n = 20) and placebo (n = 9) in patients with mild to moderate chronic heart failure (left ventricular ejection fraction
ISSN:0920-3206
1573-7241
DOI:10.1023/A:1011122929105